Our commercialization strategy involves a rapid development of treatments for both rotator cuff injuries in the shoulder and meniscus injuries of the knee joint, with an initial focus on the highly developed US Sports Medicine market.
WHO WE ARE
We have 60+ years of experience
Ortho RTI is an emerging Orthobiologics company dedicated to the development of novel therapeutic tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries.
Our Technology
Our proprietary technology platform, is a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions.
Polymer composition and PRP Patent granted under the law of United States on August 30, 2016. Patent granted under the law of European Union
PCT '129 Composition of matter:
Freeze dried chitosan and lyoprotectant for use with PRP, blood and combinations to form an injectable solution currently being prosecuted Australia granted
PCT '130 Composition and use:
Lyophilized scaffold comprising at least one polysaccharide, to have a variety of beneficial effects for tissue repair. currently being prosecuted
PRODUCT PIPELINE
Rotator Cuff Repair
There are over 600,000 rotator cuff surgeries being performed in US each year, and the number is rising at approximately 5%. Not all of these surgeries are successful: the success rate for surgery is dependent on many factors, the two most important of which are the size of the original tear and the age of the patient. Estimates have put the re-tear (or non healing) rate at an average of 50%.
The lack of apparent success for this type of shoulder surgery presents an enormous opportunity if the success rate can be improved. The cost of readmission, revision surgery and further physical therapy can often amounts to multiple (tens) of thousands of dollars: a reduction on the probability of surgical failure is therefore an extremely attractive proposition to patients, surgery centers and payers.
RESTORE-R has been designed to work with a natural fraction of a patient's blood to enhance the biological repair of the torn tendon.
Meniscal Repair
Meniscus injury is very common, and results in approximately 1,200,000 surgeries in US alone each year. The vast majority of these surgical procedures (c. 880,000) involve meniscectomy, with a minority (under 350,000) being repaired and only about 1% involving a meniscal replacement.
It is therefore clear that a product with the ability to reduce the number of meniscectomy procedures will have long term benefit for patients who are sufficiently young to have no degenerative changes in the knee joint. According to CDC, the average cost of OA in US is $5,700 per patient per year, with job related costs of up to $13billion per year. Reducing that economic burden is therefore an extremely attractive proposition, not just for the patients involved.
RESTORE-M will therefore be targeted predominantly to expand the number of procedures which involve repair, at the expense of meniscectomy procedures. It is again important to note that there is no required change to the surgical technique or procedure, but that the Ortho-M product is placed into the lesion prior to being repaired with whatever physical fixation is indicated.
ACL Repair
Injuries of the anterior cruciate ligament (ACL) occur relatively frequently, in athletes and non-athletes alike. The mechanism of injury is often a non-contact twisting of the knee that results in immediate pain and swelling. It has been estimated that there are over 100,000 ACL reconstructions performed each year in the United States, and this number is reported to be increasing. 94% of ACL injuries lead to reconstruction surgery for individuals between the ages of 15-30 totaling an estimated cost of $3 billion.
3
Patents
+75
Completed Milestones
7
Business Partners
25
Awards Won
Management - consists only of the best Talent
Claude Leduc
President & CEO
Claude Leduc
Luc Mainville
Senior Vice President & CFO
Luc Mainville
Mukesh Ahuja
Vice President - Clinical & Medical Affairs
Mukesh Ahuja
Michael Atkin
Chairman of the Board
Michael Atkin
PARTNERS
RECENT NEWS
The Product + Resources
Ortho Regenerative Technologies Inc. has entered into a global licensing agreement with Hanuman Pelican Inc.
